Free Webinar Series
MDMA Decision Debrief: Understanding the FDA’s Decision on MDMA-Assisted Therapy for PTSD
Join us for an exclusive hour with Fluence Co-Founders, Ingmar Gorman PhD and Elizabeth Nielson PhD, who served as principal investigators and study therapists on the MAPS clinical trials looking at the efficacy of MDMA for PTSD, to unpack the FDA’s announcement on the status of MDMA which is expected by August 12.
Description
The webinar starts with a discussion on the details of the recent FDA decision on the approval of MDMA-assisted therapy for medical use in treating PTSD. This groundbreaking decision is set to revolutionize the treatment landscape for PTSD and comprehensive insights into its implications for patients, healthcare providers, and the mental health industry.
Following the discussion, we opened the floor to a Q&A session. We hope you enjoy the replay.
Key Topics:
- Overview of the FDA’s decision and the process of drug approval.
- Examination of the clinical trials and research evidence supporting MDMA-AT for PTSD.
- Practical advice for clinicians on how to discuss the availability of MDMA-AT with patients, accounting for timelines of additional research and/or commercialization.
- Discussion on the regulatory, ethical, and logistical considerations of implementing MDMA-AT.
- Future perspectives on the potential for further approvals of psychedelic therapies and the evolution of psychedelic medicine.
Don’t miss this opportunity to hear from top experts in the field and gain a deeper understanding of the FDA’s decision and its profound impact on the future of PTSD treatment.
